Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures
This French 'real-world' experience shows that rVWF could be of interest in the treatment and prophylaxis of bleeding in patients with AVWS, with no clinically significant safety concern.
Authors
- Marc Trossaërt (ORCID: https://orcid.org/0000-0003-4072-839X)
- Catherine Ternisien
- Jordan Wimmer (ORCID: https://orcid.org/0009-0005-4150-1631)
- Antoine Babuty (ORCID: https://orcid.org/0000-0002-9284-7094)
- Dominique Desprez (ORCID: https://orcid.org/0009-0007-4118-0350)
- Nicolas Drillaud (ORCID: https://orcid.org/0000-0002-6500-5190)
- Marc Fouassier (ORCID: https://orcid.org/0000-0002-0964-0739)
- Agathe Herb (ORCID: https://orcid.org/0000-0003-1040-0086)
- Olivier Feugeas (ORCID: https://orcid.org/0009-0008-0089-9470)
- Léa Pierre
- Laurent Sattler (ORCID: https://orcid.org/0000-0003-2702-6246)
- Xavier Hittinger
- Anne‐Cécile Gerout
Institutions
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Strasbourg (FR)
Publication Details
- Journal
- Haemophilia
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1111/hae.15098
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.45